![McWilliams School of Biomedical Informatics](../../assets/md5images/f59dc081b7356339757ba9861fe6e1e1.jpg)
Journal Articles
Publication Date
5-1-2024
Journal
Multiple Sclerosis Journal
Abstract
BACKGROUND: Effective and safe treatment options for multiple sclerosis (MS) are still needed. Montelukast, a leukotriene receptor antagonist (LTRA) currently indicated for asthma or allergic rhinitis, may provide an additional therapeutic approach.
OBJECTIVE: The study aimed to evaluate the effects of montelukast on the relapses of people with MS (pwMS).
METHODS: In this retrospective case-control study, two independent longitudinal claims datasets were used to emulate randomized clinical trials (RCTs). We identified pwMS aged 18-65 years, on MS disease-modifying therapies concomitantly, in de-identified claims from Optum's Clinformatics
RESULTS: pwMS treated with montelukast demonstrated a statistically significant 23.6% reduction in relapses compared to non-users in 67.3% of emulated RCTs.
CONCLUSION: Real-world evidence suggested that montelukast reduces MS relapses, warranting future clinical trials and further research on LTRAs' potential mechanism in MS.
Keywords
Humans, Sulfides, Cyclopropanes, Quinolines, Acetates, Adult, Middle Aged, Female, Male, Retrospective Studies, Leukotriene Antagonists, Multiple Sclerosis, Young Adult, Case-Control Studies, Adolescent, Aged, Administrative Claims, Healthcare, Recurrence
Comments
Supplementary Materials
PMID: 38660773